Krakow, Poland – 26 March 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, today announced that it is an exhibitor at the upcoming ELRIG Research & Innovation 2019 conference taking place on the 2-3 April at the Homerton College in Cambridge, London, UK.

Throughout the whole event, Selvita’s team will be available at booth #10. It is a great opportunity to meet our representatives on-site and discuss Selvita’s capabilities in the area of integrated drug discovery services.

To contact Selvita’s delegates at this conference, please email us at

The 2019 ELRIG R&I conference will discuss how the most promising new biology is being identified and discovered and seek to explore what promising new technologies and innovations are emerging to enable this science to be effectively translated into successful therapeutics.

Additional information is available on the conference website at

Selvita Services Segment

Selvita Services Segment is a drug discovery and development partner for the pharmaceutical and biotechnology industries. It provides integrated drug discovery support starting from hit identification, hit to lead, lead optimization phase up to nomination of a preclinical candidate. The broad range of services includes medicinal and computational chemistry, custom synthesis and scale-up, in vitro pharmacology, structural biology, protein chemistry, ADME/DMPK as well as a comprehensive offer of analytical testing for APIs and drug products. In addition, Selvita Services Segment has extensive expertise in comparability studies of biosimilar drugs. Its laboratories are both GLP- and GMP-certified.

About Selvita

Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the U.S (Greater Boston, San Francisco Bay), and in the U.K. (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from the U.S. and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).

Media contact:

Malgorzata Syjud
Selvita S.A.
+48 660 797 362